)
)
)
NKILT Therapeutics Inc.
Cell therapy biotech developing a novel off-the-shelf approach with proprietary and first-in-class engineered CIR™NK cells that target HLA-G, expressed in over 50% of hematologic and solid tumors.
Our unique technology enhances NK cell potency and functional persistence to safely increase depth and duration of response, while improving patient access, scalability, speed and profitability.
)
){kind=logo}
)
){kind=logo}
){kind=logo}
)
)
)
)